Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab – was unable to improve on Opdivo alone in the RELATIVITY-098 ...

BMS said it will launch Cobenfy within the next few weeks and has set a price of $1,850 per month for the medicine, which is considerably more than the current, largely generic array of ...

2P profit rises to SAR 125.4M in 9M 2024, SAR36.9M in Q3 9 M 2024 2P gains SAR 88.5M in H1 2024, SAR 58.8M in Q2 6 M 2024 2P posts 4% rise in Q1 2024 earnings to SAR 29.7M 3 M 2024 2P’s 2023 profit ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Figure. Overview of current and in development antiplatelet agents. COX-1 indicates cyclooxygenase-1; GPVI, glycoprotein VI; PAR1, protease-activated receptor-1; PDE, phosphodiesterase; PDI, protein ...